ATHX Athersys Inc.

1.36
+0.01  (+1%)
Previous Close 1.35
Open 1.32
Price To Book 8
Market Cap 213,066,739
Shares 156,666,720
Volume 721,777
Short Ratio
Av. Daily Volume 660,994
Stock charts supplied by TradingView

NewsSee all news

  1. Athersys Names Ivor Macleod Chief Financial Officer

    CLEVELAND, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) announced today the addition of Mr. Ivor Macleod, CPA, MBA, a highly experienced pharmaceutical executive, to the Athersys leadership team. Mr.

  2. Athersys Provides Update on One-Year ARDS Study Data

    CLEVELAND, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) announced today the one-year follow-up summary results from its exploratory clinical study of the intravenous administration of MultiStem® cell

  3. Healios Receives Notification of Orphan Designation for Acute Respiratory Distress Syndrome Clinical Program

    CLEVELAND, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) announced today that its collaborator in Japan, HEALIOS K.K. ("Healios") received notification this week from the Pharmaceutical Affairs and

  4. Athersys Reports Third Quarter 2019 Results

    CLEVELAND, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) announced today its financial results for the three months ended September 30, 2019. Highlights of the third quarter of 2019 and recent events

  5. Athersys to Host Third Quarter Financial Results Call

    CLEVELAND, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) will release its third quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, November 6, 2019, and will host a

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2/3 enrollment commenced November 2017 (Japan).
Multistem - TREASURE (Japan)
Ischemic stroke
Phase 3 MASTERS-2 trial initiation announced July 31, 2018.
Multistem
Ischemic stroke
Phase 2 enrollment continues but reported May 2018 that enrollment is slower than expected.
Multistem
Acute myocardial infarction
Phase 2 ONE-BRIDGE commencement of enrolment announced April 23, 2019.
Multistem
Acute Respiratory Distress Syndrome

Latest News

  1. Athersys Names Ivor Macleod Chief Financial Officer

    CLEVELAND, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) announced today the addition of Mr. Ivor Macleod, CPA, MBA, a highly experienced pharmaceutical executive, to the Athersys leadership team. Mr.

  2. Athersys Provides Update on One-Year ARDS Study Data

    CLEVELAND, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) announced today the one-year follow-up summary results from its exploratory clinical study of the intravenous administration of MultiStem® cell

  3. Healios Receives Notification of Orphan Designation for Acute Respiratory Distress Syndrome Clinical Program

    CLEVELAND, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) announced today that its collaborator in Japan, HEALIOS K.K. ("Healios") received notification this week from the Pharmaceutical Affairs and

  4. Athersys Reports Third Quarter 2019 Results

    CLEVELAND, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) announced today its financial results for the three months ended September 30, 2019. Highlights of the third quarter of 2019 and recent events

  5. Athersys to Host Third Quarter Financial Results Call

    CLEVELAND, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) will release its third quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, November 6, 2019, and will host a

  6. Athersys to Present at 2019 Cell & Gene Meeting on the Mesa

    CLEVELAND, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) announced today that Dr. Gil Van Bokkelen, Chairman and CEO, will present at the annual Cell & Gene Meeting on the Mesa to be held October